The American Urological Association (AUA) has updated its guidelines to strengthen the recommendation for Aquablation therapy as a surgical treatment for benign prostatic hyperplasia (BPH) in men with prostate volumes of 30–80 mL, and now includes larger prostates up to 150 mL. This update reflects growing clinical evidence, including long-term trial data showing durable symptom improvement and increased adoption in clinical practice. The therapy, developed by PROCEPT BioRobotics, is recognized for its effectiveness across a broad range of prostate sizes and is supported by randomized trials comparing it to other surgical methods. This guideline update follows similar endorsements from the European Association of Urology, signaling wider acceptance of Aquablation therapy in treating BPH.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...
Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...
ASML Holdings has raised its 2026 revenue guidance midpoint from €38 billion to €44 billion and increased its gross margin midpoint from 52% to 55%, reflecting strong growth prospects. The analyst maintains a Buy rating and raises the price target fr...
Labcorp is considered a buy due to its effective rollup strategy in a fragmented lab testing industry, driving steady and predictable growth. Automation is reducing operational costs, helping to counteract healthcare pricing pressures. The company no...
